1[1]Stern DF, Hefferman PA, Weinberg RA. p185, a product of the neu proto-oncogene,is a receptorlike protein associated with tyrosine kinase activity[J]. Mol Bell Biol, 1986,6(5): 1729.
2[2]Chong D, Cooke TG, Reeve JR, et al. Quantification of EGFR and c-erbB-2 expression in preinvasive compared to invasive breast cancer[J]. Eur J Cancer, 1999,35(Suppl 4) :203.
3[3]Allred DC, Clark GM, Molina R, et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer[J]. Hum Pathol, 1992,23(9) :974.
4[4]Thomas E,Buzdar A,Theriault R,et al. Role of paclitaxel in adjuvant therapy of operable breast cancer: preliminary results of prospective randomised clinical trial[J]. Proc Am Soc Clin Oncol,2000,19:74.
5[5]Strickland LB, Dawson PJ. The hyperplasia-to-carcinoma sequence in the breast: immunohistochemical-histologic correlations [J]. Appl Immunohistochem Mol Morphol, 2000,8 (2): 9.
6[6]Cobleigh MA,Vogel CL,Tripathy D,et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metasta-tic disease [J]. J Clin Oncol, 1999,17 (9): 2639.
7[7]Slamon DJ,Leyland-Jones B,Shak S,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 [J]. N Engl J Med, 2001, 344(11):783.
8[8]Pegram M,Hsu S,Lewis G,et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for the treatment of human breast cancers[J]. Oncogene, 1999,18(13):2241.
9[9]Leyland-Jones B. Integration of Herceptininto breast cancer treatment algorithms[J]. Anti-Cancer Drugs,2002,13(suppl): 100.
10[10]Slamon D, Leyland-Jones B, Shak S, et al. Addition of Herceptin(humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer(HER2 +/MBC) markedly increases anticancer activity: a ran-domized,multinational, controlled phase Ⅲ trial [J]. Proc Am Soc Clin Oncol, 1998,17: 98a.
